Trial Profile
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Stapuldencel-T (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Cancer metastases; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms VIABLE
- Sponsors SOTIO
- 07 Apr 2021 Primary endpoint representing therapeutic effect, its time frame was changed from 124 weeks to 58 months.
- 20 Mar 2020 Status changed from active, no longer recruiting to completed.
- 19 Mar 2020 This trial has been completed in Hungary, Sweden and Latvia, according to European Clinical Trials Database record.